healthcare

Can Editas Survive After Losing Its CEO?

Editas Medicine Inc. (NASDAQ: EDIT) shares were crushed on Tuesday after the company announced that its president and chief executive, Katrine Bosley, would be stepping down from these roles effective ...
Read Full Story »

Johnson & Johnson Earnings: When Good Enough Just Isn’t Good Enough

Johnson & Johnson (NYSE: JNJ) released its fourth-quarter financial results before the markets opened on Tuesday. The health care giant said that it had in $1.97 earnings per share (EPS) ...
Read Full Story »

FDA Diabetes Treatment Vote to Determine the Fate of Lexicon Therapeutics?

Lexicon Pharmaceutics Inc. (NASDAQ: LXRX) shares fell on Friday after the U.S. Food and Drug Administration (FDA) voted to approve the firm’s type 1 diabetes treatment. Although the result from ...
Read Full Story »

Is Immunomedics Breast Cancer Treatment Doomed After This FDA Update?

Immunomedics Inc. (NASDAQ: IMMU) shares were crushed on Friday after the firm received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). Usually, CRLs can spell ...
Read Full Story »

Is Spectrum Pharma Getting Enough for Its Hematology/Oncology Portfolio?

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares made a handy gain early Thursday after the firm announced that it would be selling its portfolio of seven FDA-approved hematology/oncology products to Acrotech ...
Read Full Story »

Where Does Aptinyx Go Next After Disappointing Midstage Results for Pain Treatment?

Aptinyx Inc. (NASDAQ: APTX) shares were absolutely crushed on Wednesday after the firm reported midstage results from its clinical study in patients with painful diabetic peripheral neuropathy (DPN). Specifically, Aptinyx ...
Read Full Story »

Why CVS and Walmart Are Parting Ways

CVS Health Corp. (NYSE: CVS) has announced that it will be parting ways with megastore Walmart Inc. (NYSE: WMT). Specifically, Walmart has opted to leave the CVS Caremark pharmacy benefit management ...
Read Full Story »

Major Pharma Sees Fading Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Biotechs Scare Off Short Sellers

The short interest data are out for the most recent settlement date, December 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why the FDA Is Coming Down on Akorn

Akorn Inc. (NASDAQ: AKRX) shares dipped on Wednesday after the company received a warning letter from the U.S. Food and Drug Administration (FDA). The letter is in relation to an ...
Read Full Story »

Analyst Names Top Legalized Marijuana Stocks for 2019

The world of legalized marijuana and cannabis sales is expected to keep growing. A 2019 forecast report from Cowen now projects even stronger growth from this industry in the decade ...
Read Full Story »

Moderna Makes Big Post-IPO Strides With Pipeline Update

Moderna Inc. (NASDAQ: MRNA) shares made a handy gain early Tuesday after the company announced updates to several of its immuno-oncology and rare disease programs and outlined its 2019–2020 corporate ...
Read Full Story »

Alector Files for IPO

Alector has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No pricing details were given in the filing, although the ...
Read Full Story »

Are Loxo Shareholders Getting Enough in the Buyout?

Loxo Oncology Inc. (NASDAQ: LOXO) shares made a massive gain on Monday after it was announced that the firm would be acquired by Eli Lilly and Co. (NYSE: LLY). The ...
Read Full Story »

Why Axsome Therapeutics Depression Study Is All Smiles

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares absolutely exploded on Monday after the company announced that its midstage trial in patients with major depressive disorder (MDD) met its primary endpoint. Not ...
Read Full Story »